Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-05-26
2010-02-23
Aulakh, Charanjit S (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S020000, C544S124000, C514S231500
Reexamination Certificate
active
07666875
ABSTRACT:
The invention relates to the use of hydantoin compounds useful for treating or preventing autoimmune disorders. The present invention also provides compositions and uses thereof.
REFERENCES:
patent: 1 619 193 (2006-01-01), None
patent: WO 2004/092169 (2004-10-01), None
patent: WO 2005/023810 (2005-03-01), None
patent: WO 2006/000096 (2006-01-01), None
Balashov et al. “CCR5+and CXCR3+T cells are increased in multiple sclerosis and their Ilgands MIP-1α and IP-10 are expressed in demyelinating brain lesions”Proc. Natl. Acad. Sci. USA96:6873-6878 (1999).
Bleicher et al. “Parallel Solution- and Solid-Phase Synthesis of Spirohydantoin Derivatives as Neurokinin-1 Receptor Ligands”Bioorganic&Medicinal Chemistry Letters12:2519-2522 (2002).
International Search Report and Written Opinion for PCT/US2006/020848; date of mailing Nov. 24, 2006.
Sellebjerg et al. “CCR5 Δ 32, matrix matealloproteinase-9 and disease activity in multiple sclerosis”Journal of Neuroimmunology102:98-106 (2000).
Szabo S J et al. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell (Mar. 17, 2000), vol. 100, pp. 655-669.
Gerli R et al. In vivo activated T cells in rheumatoid synovitis. Analysis of Th1- and Th2-type cytokine production at clonal level in different stages of disease. Clinical and Experimental Immunology (2002), vol. 129, pp. 549-555.
Skapenko A et al. The role of the T cell in autoimmune inflammation. Arthritis Research & Therapy (Mar. 2005), vol. 7, supp. 2, pp. S4-S14.
Dunn S E et al. Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. The Journal of Experimental Medicine (Feb. 20, 2006), vol. 203, No. 2, pp. 401-412.
International Preliminary Report on Patentability and Written Opinion for PCT/US2006/020848; date of mailing Dec. 27, 2007.
Weigmann B and Neurath N. T-bet as a possible therapeutic target in autoimmune disease. Expert Opin. Ther. Targets 6, 619 (2002) (abstract only).
Neurath M et al. The Transcription Factor T-bet Regulates Mucosal T Cell Activation in Experimental Colitis and Crohn's Disease. J. Exp. Med. 195, 1129 (2002).
Peng S et al. T-bet regulates IgG class switching and pathogenic autoantibody production. Proc. Natl. Acad. Sci. USA 99, 5545 (2002).
Juedes A et al. T-bet Controls Autoaggressive CD8 Lymphocyte Responses in Type 1 Diabetes, J. Exp. Med. 199, 1153 (2004).
Bettelli E et al. Loss of T-bet, But Not STAT1, prevents the Development of Experimental Autoimmune Encephalomyelitis. J. Exp. Med. 200, 79 (2004).
Buono C et al. T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses. Proc. Natl. Acad. Sci. USA 102, 1596 (Feb. 2005).
Carlson Eric
Chen Qian
Davis Heather
Gallagher, Jr. Brian M.
Schiller Shawn
Aulakh Charanjit S
Eisai R&D Management Co., Ltd.
Myers Bigel Sibley & Sajovec P.A.
LandOfFree
Hydantoin compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hydantoin compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydantoin compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4211814